These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1379106)

  • 41. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
    Fourcade RO
    Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The efficacy of alfuzosin (dalfaz) in patients with benign prostatic hyperplasia].
    Tkachuk VN; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (2):38-40. PubMed ID: 9577703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.
    Andersen M; Dahlstrand C; Høye K
    Eur Urol; 2000 Oct; 38(4):400-9. PubMed ID: 11025377
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Alfuzosin in the treatment of benign prostatic hypertrophy].
    Jardin A
    J Urol (Paris); 1993; 99(6):308-10. PubMed ID: 7516375
    [No Abstract]   [Full Text] [Related]  

  • 45. Effect of alfuzosin on female primary bladder neck obstruction.
    Athanasopoulos A; Gyftopoulos K; Giannitsas K; Perimenis P
    Int Urogynecol J Pelvic Floor Dysfunct; 2009 Feb; 20(2):217-22. PubMed ID: 18982236
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.
    Roehrborn CG
    Urology; 2001 Dec; 58(6 Suppl 1):55-63; discussion 63-4. PubMed ID: 11750253
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effectiveness of various alfuzosin schedules in patients with benign prostatic hyperplasia (BPH)].
    Loran OB; Rasner PI; Kosko D; Pushkar' DIu
    Urologiia; 2001; (1):8-10. PubMed ID: 11233234
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group.
    Hansen BJ; Meyhoff HH; Nordling J; Mensink HJ; Mogensen P; Larsen EH
    Scand J Urol Nephrol; 1996 Oct; 30(5):373-7. PubMed ID: 8936626
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
    Lee M
    Am J Health Syst Pharm; 2003 Jul; 60(14):1426-39. PubMed ID: 12892027
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bladder-neck opening test in spinal cord injury patients using a new i.v. alpha-blocking agent, alfuzosin.
    Cramer P; Neveux E; Régnier F; Depassio J; Bérard E
    Paraplegia; 1989 Apr; 27(2):119-24. PubMed ID: 2566147
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Single dose methodology to assess the influence of an alpha1-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia.
    Curtis SP; Eardley I; Boyce M; Larson P; Haesen R; Gottesdiener K; Gertz BJ
    Br J Clin Pharmacol; 2000 Mar; 49(3):269-73. PubMed ID: 10718783
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia.
    Chapple CR; Stott M; Abrams PH; Christmas TJ; Milroy EJ
    Br J Urol; 1992 Sep; 70(3):285-94. PubMed ID: 1384919
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities.
    de la Rosette JJ; Karthaus HF; van Kerrebroeck PE; de Boo T; Debruyne FM
    Eur Urol; 1992; 22(3):222-7. PubMed ID: 1361435
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Alfuzosin in benign prostatic hyperplasia. A new principle is evaluated. Report of a study].
    Fortschr Med Suppl; 1995; 166():1-12. PubMed ID: 7537599
    [No Abstract]   [Full Text] [Related]  

  • 57. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
    Wyllie MG
    BJU Int; 2003 Dec; 92(9):1044; author reply 1044-5. PubMed ID: 14632873
    [No Abstract]   [Full Text] [Related]  

  • 58. Alfuzosin (10 mg) does not affect blood pressure in young healthy men.
    Mondaini N; Giubilei G; Ungar A; Gontero P; Cai T; Gavazzi A; Bartoletti R; Geppetti P; Carini M
    Eur Urol; 2006 Dec; 50(6):1292-6; discussion 1297-8. PubMed ID: 16837126
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Assessment of the effects of alfuzosin on miction with dynamic echography].
    Milani M; Mautone A; Tucci G; Gentili G
    Arch Ital Urol Androl; 1994 Sep; 66(4 Suppl):193-7. PubMed ID: 7534166
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The evaluation of the effects of bunazosin hydrochloride in the treatment of prostatic hyperplasia].
    Fujita T; Ohshima S; Asano H; Ono Y; Kinukawa T; Kato N; Hirabayashi S
    Hinyokika Kiyo; 1992 May; 38(5):613-21. PubMed ID: 1376962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.